SKP2 Antibody (YA5059)
(Synonyms: SKP2; FBXL1; S-phase kinase-associated protein 2; Cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2)SKP2 Antibody (YA5059) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SKP2.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, IHC-P
-
Reactivity :
Mouse, Rat
-
Formulation:
Supplied in ascitic fluid containing 0.03% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:50-1:100 |
Product Details
SKP2 Antibody (YA5059) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SKP2.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityMouse, Rat
-
Observed Molecular WeightObserved band size: 55 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 48 kDa
Purified recombinant fragment of SKP2 expressed in E. Coli. The exact sequence is proprietary to MCE.
Endogenous
Ascitic Fluid
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in ascitic fluid containing 0.03% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Skp2 (S-phase kinase-associated protein 2) is an F-box protein that functions as the substrate-recognition component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex and regulates proteasome-dependent turnover of key cell-cycle regulators, most notably the cyclin-dependent kinase inhibitor p27^Kip1^[1][1]. Mechanistically, Skp2 promotes ubiquitination and degradation of phosphorylated p27, thereby facilitating G1/S transition and sustained cellular proliferation[1][2]. Through its E3 ligase activity, Skp2 has emerged as a central regulator of cell-cycle progression and oncogenic signaling pathways that influence tumor growth, survival, and stem-cell-associated phenotypes[1][3]. In cancer models, genetic or pharmacological inhibition of Skp2 suppresses tumor cell survival, impairs cancer stem cell maintenance, and reduces tumor progression, supporting its utility as an experimental target for mechanistic and translational studies[1]. Compared with related F-box proteins, Skp2 is distinguished by its requirement for the accessory protein Cks1 during efficient recognition and ubiquitination of p27, highlighting a unique substrate-recruitment mechanism within the SCF ubiquitin ligase family[2]. This functional specificity has motivated the development of Skp2-directed inhibitors and chemical probes designed to disrupt Skp2-mediated p27 ubiquitination and degradation[4][5]. Therefore, Skp2 represents an important molecular node linking ubiquitin-mediated proteolysis, cell-cycle control, and cancer-associated biological processes, making it a valuable target for experimental research and therapeutic investigation[1][3].
-
Subcellular Localization
Cytoplasm; Nucleus
-
Isoforms & Post-Translational Modification
Q13309 has 3 isomers: Q13309-1: 47761 Da (predicted); Q13309-2: 46576 Da (predicted); Q13309-4: 23763 Da (predicted).
Phosphorylated on serine and threonine resudues in response to DNA damage, promoting 'Lys-63'-linked ubiquitination of NBN;Ubiquitinated by the APC/C complex, leading to its degradation by the proteasome. Deubiquitinated by USP13;Acetylation at Lys-68 and Lys-71 increases stability through impairment of APC/C-mediated proteolysis and promotes cytoplasmic retention. Deacetylated by SIRT3 -
Subunit
Part of a SCF(SKP2) complex consisting of CUL1, RBX1, SKP1 and SKP2. Component of a SCF(SKP2)-like complex containing CUL1, SKP1, TRIM21 and SKP2. Interacts directly with CUL1 and SKP1. Interacts with CKS1. Interacts with ASB2 which is the substrate-recognition component of a probable ECS E3 ubiquitin-protein ligase complex; ASB2 is likely to bridge the formation of dimeric E3-ubiquitin-protein ligase complexes composed of an ECS complex and an SCF(SKP2) complex (PubMed:21119685). Interacts with the cyclin-A-CDK2 complex. Interacts with ORC1, phosphorylated CDT1, phosphorylated RBL2, ELF4, phosphorylated RAG2, FOXO1, UBP43, MYC, TOB1, TAL1 and KMT2A/MLL1. Interacts with TRIM21. Interacts with cyclin-E (By similarity). Interacts with IFI27; promotes the ubiquitin-mediated proteasomal degradation of hepatitis C virus/HCV non-structural protein NS5A (PubMed:27194766). Interacts with CARM1 (By similarity)
-
SwissProt ID
-
Synonyms
SKP2; FBXL1; S-phase kinase-associated protein 2; Cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2
Documentation
[1]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
[2]. Kiros M, et al. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis. Virol J. 2023 Oct 25;20(1):243. [Content Brief]
[3]. Cai Z, et al. The Skp2 Pathway: A Critical Target for Cancer Therapy. Semin Cancer Biol. 2020 Dec;67(Pt 2):16-33. [Content Brief]
[4]. Aye Y, et al. Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers. Chem Biol. 2012 Jul 27;19(7):799-805. [Content Brief]
[5]. Lough L, et al. Chemical probes of Skp2-mediated p27 ubiquitylation and degradation. Medchemcomm. 2018 Jun 11;9(7):1093-1104. [Content Brief]
Powered by Bioz
